WEINSTEIN ROBERT — SEC insider filings
SEC reporting owner CIK 1213709. 29 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers all 29 filings on record, filed 2020-11-27 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 50,000 shares, $12,425 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 4 legs across 4 filings — 180,000 shares, $239,787 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 38.
- Largest priced transaction: sale of 63,000 shares @ $1.43 ($90,210) in XWELL, Inc., filed 2021-10-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| XWELL, Inc. (XWEL) | Director | 14 | 2 legs · 50,000 sh · $12,425 | 3 legs · 153,000 sh · $208,146 | 12 |
| TAO Synergies Inc. (TAOX) | Chief Financial Officer | 8 | — | 1 leg · 27,000 sh · $31,641 | 10 |
| Neurotrope, Inc. (NTRP) | See Remarks | 2 | — | — | 9 |
| PharmaCyte Biotech, Inc. (PMCB) | Director | 5 | — | — | 7 |
Insider filings — WEINSTEIN ROBERT
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | TAO Synergies Inc. (TAOX) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-09-02 | 4 | XWELL, Inc. (XWEL) | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2026-07-17 | 4/A | PharmaCyte Biotech, Inc. (PMCB) | Other (J): 0 (derivative) | EDGAR |
| 2026-05-19 | 4 | TAO Synergies Inc. (TAOX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | PharmaCyte Biotech, Inc. (PMCB) | Grant/award (A): 119,170 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | XWELL, Inc. (XWEL) | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2025-12-12 | 4 | PharmaCyte Biotech, Inc. (PMCB) | Grant/award (A): 75,000 @ $0 · Tax withholding (F): 33,750 @ $1.02 · Grant/award (A): 63,233 (derivative) @ $0 | EDGAR |
| 2025-10-17 | 4 | TAO Synergies Inc. (TAOX) | Grant/award (A): 10,000 @ $0 · Tax withholding (F): 4,000 @ $7.23 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | TAO Synergies Inc. (TAOX) | Grant/award (A): 15,410 @ $0 · Tax withholding (F): 6,164 @ $7.85 | EDGAR |
| 2025-06-03 | 4 | XWELL, Inc. (XWEL) | Grant/award (A): 107,407 · Grant/award (A): 117,886 (derivative) @ $0 | EDGAR |
| 2024-11-18 | 4 | XWELL, Inc. (XWEL) | Grant/award (A): 30,825 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | PharmaCyte Biotech, Inc. (PMCB) | Grant/award (A): 38,009 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | PharmaCyte Biotech, Inc. (PMCB) | Grant/award (A): 61,248 (derivative) @ $0 | EDGAR |
| 2023-05-31 | 4 | XWELL, Inc. (XWEL) | Purchase (P): 25,000 @ $0.25 | EDGAR |
| 2023-05-30 | 4 | XWELL, Inc. (XWEL) | Purchase (P): 25,000 @ $0.25 | EDGAR |
| 2023-01-09 | 4/A | XWELL, Inc. (XWEL) | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2023-01-09 | 4 | XWELL, Inc. (XWEL) | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2022-12-20 | 4 | Synaptogenix, Inc. (SNPX) | Sale (S): 27,000 @ $1.17 | EDGAR |
| 2022-12-01 | 4/A | Synaptogenix, Inc. (SNPX) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-11-17 | 4 | Synaptogenix, Inc. (SNPX) | Grant/award (A): 96,000 (derivative) @ $0 | EDGAR |
| 2022-04-22 | 4 | XpresSpa Group, Inc. (XSPA) | Sale (S): 45,000 @ $1.06 | EDGAR |
| 2022-01-31 | 4 | XpresSpa Group, Inc. (XSPA) | Grant/award (A): 31,250 @ $0 · Grant/award (A): 46,875 (derivative) @ $0 | EDGAR |
| 2022-01-21 | 4 | XpresSpa Group, Inc. (XSPA) | Sale (S): 45,000 @ $1.56 | EDGAR |
| 2021-10-22 | 4 | XpresSpa Group, Inc. (XSPA) | Sale (S): 63,000 @ $1.43 | EDGAR |
| 2021-07-30 | 4 | XpresSpa Group, Inc. (XSPA) | Grant/award (A): 200,000 @ $0 | EDGAR |
| 2021-07-15 | 4 | Synaptogenix, Inc. (SNPX) | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2021-01-06 | 4 | XpresSpa Group, Inc. (XSPA) | Grant/award (A): 28,235 @ $0 · Grant/award (A): 43,077 (derivative) @ $0 | EDGAR |
| 2020-12-03 | 4 | Neurotrope, Inc. (NTRP) | Disposition to issuer (D): 3,953 · Disposition to issuer (D): 20,313 (derivative) · Disposition to issuer (D): 1,303 (derivative) · Disposition to issuer (D): 3,125 (derivative) · Disposition to issuer (D): 7,768 (derivative) · Disposition to issuer (D): 18,945 (derivative) · +2 more | EDGAR |
| 2020-11-27 | 4 | Neurotrope, Inc. (NTRP) | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1213709 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs